Life Sciences & Healthcare




ReNeuron has been a client of Buchanan since 2010. ReNeuron is quoted on the London Stock Exchange’s AIM Market and is a leading UK-based clinical stage stem cell therapy company.

As a pioneer in stem cell therapies, Buchanan’s communications programme has helped investors to understand that ReNeuron is now translating exciting stem cell science into biopharmaceutical products to treat serious disease conditions such as stroke, where the patient populations are large and where patients have few if any alternative treatments available to them.

The company’s therapeutic candidates for stroke disability and critical limb ischaemia are in clinical development and its cell-based treatment for the blindness-causing disease, retinitis pigmentosa, is about to commence clinical development in the US. ReNeuron is also advancing a proprietary platform technology to exploit nanoparticles (exosomes) secreted by stem cells as potential new drug candidates targeting a range of cancers.

Buchanan’s close working relationship with the ReNeuron team has led to high profile and positive media coverage such as when the company conducted a ground-breaking first-in-man clinical trial of ReN001, its stem cell therapy for the treatment of patients left disabled by the effects of a stroke late in 2010.

Buchanan continues to raise ReNeuron’s profile with investors and media as one of the most exciting, cutting edge UK life sciences companies today